Concepedia

Jared N. Cumming

JN

Statistics

Publications

31

Citations

3.3K

H-Index

28

Active since

1995

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Johns Hopkins University

Johns Hopkins Medicine

Quantitative BioSciences

United States Military Academy

Jared N. Cumming is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, medicinal chemistry, and pharmacy.

ORCID

Publications per year

1995–2022

31

Publications

31

An orally available non-nucleotide STING agonist with antitumor activity

Bo‐Sheng Pan, Samanthi A. Perera, Jennifer Piesvaux et al. · Science · 2020 · 660 citations

, , +16

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients

Matthew Kennedy, Andrew W. Stamford, Xia Chen et al. · Science Translational Medicine · 2016 · 417 citations

, , +17

Evidence for Fe(IV):O in the Molecular Mechanism of Action of the Trioxane Antimalarial Artemisinin

Gary H. Posner, Jared N. Cumming, Poonsakdi Ploypradith et al. · Journal of the American Chemical Society · 1995 · 173 citations

, , +8

Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)–A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer’s Disease

Jack D. Scott, Sarah W. Li, Andrew P. J. Brunskill et al. · Journal of Medicinal Chemistry · 2016 · 165 citations · Full text

, , +17

Structure based design of iminohydantoin BACE1 inhibitors: Identification of an orally available, centrally active BACE1 inhibitor

Jared N. Cumming, Elizabeth M. Smith, Lingyan Wang et al. · Bioorganic & Medicinal Chemistry Letters · 2012 · 154 citations · Full text

, , +14

1–5 of 31